SCHEMBL25212950

SCHEMBL25212950

CC(C)(C)OC(=O)NCCC(C)(C)C(=O)OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.55
IDO1 P14902 1/20 0.54
LMNA P02545 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAPT P10636 3/20 0.48
HTT P42858 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.46
SIGMAR1 Q99720 2/20 0.44
POLB P06746 1/20 0.44
MAPK1 P28482 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA7 P43166 1/20 0.44
CA14 Q9ULX7 1/20 0.44
CTSS P25774 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
PPARA Q07869 1/20 0.44
ALDH1A1 P00352 1/20 0.43
RECQL P46063 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30859137 0.90 MAPT (0.55) SYKIDO1LMNASMN1; SMN2MAPT
SCHEMBL4181948 0.86 SYK (0.57) SYKIDO1LMNASMN1; SMN2MAPT
SCHEMBL15202883 0.85 SYK (0.64) SYKIDO1LMNASMN1; SMN2MAPT
SCHEMBL6390091 0.83 ALDH1A1 (0.49) LMNASMN1; SMN2MAPTHTTMAPK1
SCHEMBL13938297 0.82 HTT (0.65) SYKIDO1LMNASMN1; SMN2MAPT
SCHEMBL13480435 0.82 MAPT (0.65) SYKIDO1LMNASMN1; SMN2MAPT
SCHEMBL25243786 0.82 SYK (0.42) SYKIDO1MAPTHTTL3MBTL1
SCHEMBL31300270 0.82 MAPT (0.52) SYKIDO1LMNASMN1; SMN2MAPT
SCHEMBL3955009 0.81 SYK (0.57) SYKIDO1LMNASMN1; SMN2MAPT
SCHEMBL15679441 0.81 MAPT (0.64) SYKIDO1LMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4566608-A2 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION Gilead Sciences, Inc. (US) 2025-06-11 EP disclosed
US-20250179102-A1 THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. 2025-06-05 US disclosed
EP-4440702-B1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES INC (US) 2025-05-21 EP disclosed
EP-4445900-B1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES INC (US) 2025-05-21 EP disclosed
EP-4445900-A2 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION Gilead Sciences, Inc. (US) 2024-10-16 EP disclosed
EP-4440702-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. (US) 2024-10-09 EP disclosed
CN-118369325-A Therapeutic compounds for HIV virus infection 吉利德科学公司 2024-07-19 CN disclosed
US-20240132527-A1 THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. 2024-04-25 US disclosed
US-11787825-B2 Therapeutic compounds for HIV virus infection GILEAD SCIENCES, INC. (US) 2023-10-17 US disclosed
US-20230203069-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. 2023-06-29 US disclosed
WO-2023102239-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. (US) 2023-06-08 WO disclosed
WO-2023102239-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. (US) 2023-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179102-A1 THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION CD4, HAVCR2, MAVS SYK 2998/4885IDO1 2036/4885LMNA 3425/4885
US-11787825-B2 Therapeutic compounds for HIV virus infection HAVCR2, MAVS, CD4 SYK 3490/4885IDO1 2452/4885LMNA 3518/4885
US-20230203069-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION HAVCR2, MAVS, CD4 SYK 3490/4885IDO1 2452/4885LMNA 3518/4885
US-20240132527-A1 THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION CD4, HAVCR2, MAVS SYK 2998/4885IDO1 2036/4885LMNA 3425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.